TheraCryf plc to Announce Half-Year Results on 3 December 2025

Evgen Pharma ( (GB:TCF) ) has provided an update.

TheraCryf plc announced the release of its half-year results for the period ending 30 September 2025, scheduled for 3 December 2025. A live presentation will be held for existing and potential shareholders, featuring key company executives. This announcement is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and investor relations.

Spark’s Take on GB:TCF Stock

According to Spark, TipRanks’ AI Analyst, GB:TCF is a Neutral.

Evgen Pharma’s overall stock score of 49 reflects ongoing financial and operational challenges, including declining revenues and losses. While the technical analysis shows mixed momentum, recent corporate events provide a positive outlook with strategic initiatives aimed at improving financial stability and advancing key drug development programs.

To see Spark’s full report on GB:TCF stock, click here.

More about Evgen Pharma

TheraCryf plc is a clinical stage drug development company focused on neuropsychiatry and oncology, with a broad pipeline addressing conditions such as addiction, anxiety, fatigue, narcolepsy, glioblastoma, and neurodevelopmental disorders. The company aims to generate compelling data to reach preclinical or clinical proof of concept and partners with mid-size to large pharmaceutical companies for larger trials and commercialization. It collaborates with major universities and hospitals and is headquartered in Alderley Park, Cheshire, trading on AIM under the ticker symbol TCF.

Average Trading Volume: 4,402,158

Technical Sentiment Signal: Sell

Current Market Cap: £4.08M

For a thorough assessment of TCF stock, go to TipRanks’ Stock Analysis page.